Cite
HARVARD Citation
Buteau, J. et al. (2022). PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet oncology. 23 (11), pp. 1389-1397. [Online].